Last update 08 May 2025

LY6G6D x CD3ε

Basic Info

Related Targets
LY6G6DCD3ε

Related

1
Drugs associated with LY6G6D x CD3ε
Linclatamig
Target
CD3ε x LY6G6D
Mechanism
CD3ε inhibitors [+1]
Active Org.-
Originator Org.
Genentech, Inc.Genentech, Inc.
Active Indication-
Inactive Indication
Colorectal Cancer [+1]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with LY6G6D x CD3ε
CTIS2023-503409-12-00
/ Not yet recruitingPhase 1
- GO41751
NCT04468607
/ CompletedPhase 1
A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer
100 Clinical Results associated with LY6G6D x CD3ε
Login to view more data
100 Translational Medicine associated with LY6G6D x CD3ε
Login to view more data
0 Patents (Medical) associated with LY6G6D x CD3ε
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free